Abiopharma

LYELL IMMUNOPHARMA, INC. (LYEL)

Symbol	LYEL
Name	LYELL IMMUNOPHARMA, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	201 HASKINS WAY,SUITE 301, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone	+1 650 695-0677
Fax	—
Email	—
Website	https://www.lyell.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001806952
Description	Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Additional info from NASDAQ: Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

2026-07-01 16:37

Innovative Cellular Therapeutics Holdings Ltd 🔴 sold 76.0K shares of Lyell Immunopharma, Inc. (LYEL) Transaction Date: Jun 29, 2026 | Filing ID: 027140

2026-06-25 12:00

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

2026-06-19 01:59

Innovative Cellular Therapeutics Holdings Ltd 🔴 sold 66.5K shares of Lyell Immunopharma, Inc. (LYEL) Transaction Date: Jun 15, 2026 | Filing ID: 025796

2026-06-15 22:37

Seely Lynn 🔴 sold 388 shares of Lyell Immunopharma, Inc. (LYEL) at $18.91 Transaction Date: May 11, 2026 | Filing ID: 000003

2026-06-15 22:35

Lee Gary K. 🔴 sold 130 shares of Lyell Immunopharma, Inc. (LYEL) at $18.92 Transaction Date: May 11, 2026 | Filing ID: 000003

2026-06-15 22:34

Hill Stephen J. 🔴 sold 89 shares of Lyell Immunopharma, Inc. (LYEL) at $18.92 Transaction Date: May 11, 2026 | Filing ID: 000003

2026-06-15 22:32

Bulis Veronica Sanchez 🔴 sold 217 shares of Lyell Immunopharma, Inc. (LYEL) at $18.91 Transaction Date: May 11, 2026 | Filing ID: 000004

2026-06-12 20:25

RIEFLIN WILLIAM JL 🟢 acquired 9.2K shares (1 derivative) of Lyell Immunopharma, Inc. (LYEL) at $13.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

2026-06-12 20:23

Ramachandra Sumant 🟢 acquired 9.2K shares (1 derivative) of Lyell Immunopharma, Inc. (LYEL) at $13.22 Transaction Date: Jun 10, 2026 | Filing ID: 000002

2026-06-12 20:22

NABEL ELIZABETH G 🟢 acquired 9.2K shares (1 derivative) of Lyell Immunopharma, Inc. (LYEL) at $13.22 Transaction Date: Jun 10, 2025 | Filing ID: 000004

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07188558	A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell T…	Phase3	Large B-cell Lymphoma	Recruiting	2026-01-12	2032-01-01	ClinicalTrials.gov
NCT06153095	A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupu…	Phase1	Systemic Lupus Erythematosus	Withdrawn	2024-02-15	2025-01-09	ClinicalTrials.gov
NCT05891197	A Biomarker Screening Protocol for Participants With Solid Tumors	—	Triple Negative Breast Cancer	Terminated	2023-05-19	2025-02-05	ClinicalTrials.gov
NCT05826535	Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma	Phase1	Relapsed Non-Hodgkin Lymphoma	Recruiting	2023-05-09	2031-06-30	ClinicalTrials.gov
NCT05573035	A Study to Investigate LYL845 in Adults With Solid Tumors	Phase1	Melanoma	Terminated	2022-12-19	2025-01-09	ClinicalTrials.gov
NCT05319314	LYL273 for Patients With Relapsed or Refractory mCRC	Phase1	Colorectal Cancer	Recruiting	2022-08-01	2032-06-01	ClinicalTrials.gov
NCT05274451	A Study to Investigate LYL797 in Adults With Solid Tumors	Phase1	Triple Negative Breast Cancer	Terminated	2022-03-29	2024-11-27	ClinicalTrials.gov

Total clinical trials: 7

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
LYL273	Other	Phase PHASE1	Colorectal Cancer	RECRUITING	NCT05319314
lisocabtagene maraleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
axicabtagene ciloleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
rondecabtagene autoleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
LYL273	Other	Phase PHASE1	Colorectal Cancer	RECRUITING	NCT05319314
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
IMPT-514	Other	Phase PHASE1	Systemic Lupus Erythematosus	WITHDRAWN	NCT06153095
LYL845	Other	Phase PHASE1	Melanoma	TERMINATED	NCT05573035
LYL797	Other	Phase PHASE1	Triple Negative Breast Cancer	TERMINATED	NCT05274451
GCC19CART	Other	Phase PHASE1	Colorectal Cancer	RECRUITING	NCT05319314
lisocabtagene maraleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
axicabtagene ciloleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
rondecabtagene autoleucel	Other	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Cyclophosphamide	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Rondecabtagene autoleucel (ronde-cel)	Other	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
lisocabtagene maraleucel	BIOLOGICAL	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
axicabtagene ciloleucel	BIOLOGICAL	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
rondecabtagene autoleucel	BIOLOGICAL	Phase PHASE3	Large B-cell Lymphoma	RECRUITING	NCT07188558
IMPT-514	BIOLOGICAL	Phase PHASE1	Systemic Lupus Erythematosus	WITHDRAWN	NCT06153095
Cyclophosphamide	DRUG	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
Fludarabine	DRUG	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
LYL314	DRUG	Phase PHASE1	Relapsed Non-Hodgkin Lymphoma	RECRUITING	NCT05826535
LYL845	BIOLOGICAL	Phase PHASE1	Melanoma	TERMINATED	NCT05573035
GCC19CART	DRUG	Phase PHASE1	Colorectal Cancer	RECRUITING	NCT05319314
LYL797	BIOLOGICAL	Phase PHASE1	Triple Negative Breast Cancer	TERMINATED	NCT05274451

Total products: 85